Cambridge biotech XTuit Pharmaceuticals just raised a $22 million Series A, according to a news release. The startup’s therapeutics target the disease-inducing microenvironment of cancers and fibrotic disease.
The funding will advance XTuit’s work in cancer immunotherapy and cirrhosis – with microenvironment-activated drugs that reverse disease progression, it said. It’s also building out a tissue-based biomarker platform to gauge efficacy.
The scientific basis of the company comes from a trio of lauded researchers, founded in 2011 by Harvard professor Rakesh Jain, MIT chemical engineering professor Bob Langer and Salk Institute professor Ronald Evans (who, notably, is in the midst of launching another stealth startup – Metacrine).
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
This is XTuit’s official emergence from stealth mode, but MedCity News was the first to report on XTuit’s activity back in December.
Funding comes from New Enterprise Associates, Polaris Partners, CTI Life Sciences, Arcus Ventures and Omega Funds.
